There was an increasing trend over time (2011: 53.2% and 68.8% MCO use in the Down syndrome and no developmental disability cohorts, respectively; 2019: 76.0% and 81.1% MCO use in the Down syndrome and no developmental disability cohorts, respectively).
1
—
—